| Objective: This article is to observe the clinical effect of the Didang decoction prescriptioncapsule in the treatment of the type III of silent myocardial ischemia of blood stasis type.We will observe its effect on the myocardial ischemia, total ischemia burden and the heartrate variability through the dynamic electrocardiogram. Meanwhile, we will observe thechanges of the apolipoprotein, lipoprotein (α) and hs-CRP.Methods:60cases of type III of silent myocardial ischemia and blood stasis are randomlydivided into two groups.30cases are in treatment group, which will be treated with2Didang decoction capsule on the basis of conventional western medicine,3times a day.And the other30cases are in the control group,which will be treated with the routinewestern medicine. Both of the two groups will be treated for4weeks.Results: After4weeks’ treatment, the myocardial ischemia, the myocardial ischemicthreshold variability, the total myocardial ischemia episodes, the maximum displacementof ST segment depression, each array ischemia duration and the total ischemia burden weresignificantly reduced (P <0.01) in both of the two groups. The heart muscle ischemiathreshold, the myocardial ischemic threshold variability and the total ischemia burden ofthe treatment group were significantly lower than the control group and there was asignificant difference in the treatment group compared with control group (all P <0.05).The results above indicated that the Didang decoction prescription capsule canfurther improve the myocardial ischemic burden compared with the conventional western medicine. Besides, the heart rate variability (SDNN, SDANN, rMSSD, pNN50), theapolipoprotein (ApoA1, ApoB, ApoA1/ApoB)and the hs-CRP were improved significantlyin both of the treatment group and the control group after4weeks’ treatment and thedifferences were statistically significant (P <0.01or P <0.05). And the improvement ofthe Didang decoction capsule group was more significantly than the conventional westernmedicine group, with statistical significance as compared with the conventional westernmedicine group (P <0.05or P<0.01). The Lp (a) of the Didang decoction capsule groupwas improved more significantly and its difference was statistically significant (P <0.05),while the difference of conventional western medicine group was not statisticallysignificant.Conclusions: Didang decoction capsule can effectively reduce the total ischemia burdenand improve the myocardial ischemia of the type III of silent myocardial ischemia andblood stasis type thermal resistance network patients. At the same time, Didang decoctioncapsule can effectively improve the heart rate variability, the blood lipid metabolism andthe hs-CRP level and it can also suppress the inflammatory response of the type III silentmyocardial ischemia patients. |
PDF Full Text Request